P-57AS3

Star0

DB06569ExperimentalSmall molecule

Investigated for use/treatment in obesity.

Primary indication: Investigated for use/treatment in obesity.Curator reviewed
Formula / weight: C₄₇H₇₄O₁₅ · 879.094 g/mol (avg)
Code names: P57 · P-57AS3

Resolves to

Compound

UNII870A6Q6XVJCAS384329-61-7

Structure

InChIKeyCBMQKMMZBOSHHP-VXXSQTRDSA-NSMILES

[H][C@@]12CC=C3C[C@H](CC[C@]3(C)[C@@]1([H])C[C@@H](OC(=O)C(\C)=C\C)[C@]1(C)[C@H](CC[C@]21O)C(C)=O)O[C@H]1C[C@H](OC)[C@H](O[C@H]2C[C@H](OC)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](OC)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1

Transporters

P33527ABCC1P08183ABCB1Q92887ABCC2

What you can answer from here — as of July 03, 2026

3TransportersSubstrate / inhibitor direction, not just membership

Listed above

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of P-57AS3, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account